May 2022 Newsletter

News

Read the May 2022 Newsletter.

Read more

New clinical trial for GD3

Uncategorized

Patients 12 years and older are needed for a clinical research study testing an orally administered treatment in Gaucher disease type 3. This study will evaluate whether an investigational treatment, a substrate reduction therapy, is effective in treating patients 12 years and older with Gaucher disease type 3 while also further evaluating the study drug’s […]

Read more

Reflections on the IGA Board and Biennial Meetings

Events|News

Our Communications and Campaigns Officer Harry Albright has written a blog post about the recent IGA board and biennial meetings. Read it here.

Read more

April 2022 Newsletter

News

Read the April 2022 Newsletter.

Read more

GARDIAN Launch Day

News

The GARDIAN Registry will today begin enrolling patients affected by type 2 & 3 Gaucher Disease to collect data on the realities of the condition and drive improvements in standards of care. Watch this film on why you should take part and visit www.gardianregistry.org to register.

Read more

  • Categories

  • Select Date Range

× How can I help you?